New drug shows promise for Hard-to-Treat blood cancer in early trial

NCT ID NCT04773522

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 22 times

Summary

This early-phase study tested a new drug called JNJ-64407564 in 15 Japanese patients with multiple myeloma that had come back or stopped responding to other treatments. The drug is a special antibody that helps the immune system attack cancer cells. The main goal was to check safety and find the right dose for future studies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Iwate Medical University Hospital

    Shiwa-gun, 028-3695, Japan

  • Japanese Red Cross Medical Center

    Shibuya City, 150-8935, Japan

  • Nagoya City University Hospital

    Nagoya, 467 8602, Japan

  • National Cancer Center Hospital East

    Kashiwa, 277 8577, Japan

  • National Hospital Organization Okayama Medical Center

    Okayama, 701-1192, Japan

  • Shonan Kamakura General Hospital

    Kamakura-shi, 247-8533, Japan

Conditions

Explore the condition pages connected to this study.